SG Americas Securities LLC Has $11.33 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

SG Americas Securities LLC lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 628,510 shares of the company’s stock after selling 22,974 shares during the period. SG Americas Securities LLC owned 0.06% of Teva Pharmaceutical Industries worth $11,326,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $30,000. Beach Investment Counsel Inc. PA bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $48,000. Byrne Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $52,000. Finally, Industrial Alliance Investment Management Inc. bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the subject of several analyst reports. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Wednesday, July 10th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Thursday. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Stock Up 0.6 %

NYSE:TEVA traded up $0.11 during trading hours on Friday, reaching $17.49. The company had a trading volume of 4,669,458 shares, compared to its average volume of 6,931,503. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The firm has a market cap of $19.81 billion, a price-to-earnings ratio of -42.63, a P/E/G ratio of 1.21 and a beta of 0.88. The business’s 50-day simple moving average is $17.83 and its two-hundred day simple moving average is $16.35. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.